glp 1 slimming drops US states drop Medicaid coverage of GLP-1 weight-loss drugs as demand rises | US healthcare US states drop Medicaid coverage

Inflammatory bowel diseases (IBD), including Crohns disease (CD) and ulcerative colitis (UC), are chronic, relapsing, intestinal inflammatory disorders with complex and yet unrevealed pathogenesis in which genetic, immunological, and environmental factors play a role

In contrast, no benefits on the rate of decline in glomerular filtration rate have been seen in trials of DPP-4 inhibitors, perhaps because the renal actions of DPP-4 inhibitors are primarily mediated by potentiation of SDF-1, not GLP-1

Very few include older adults at high risk

From the ADA meeting yesterday, presentations and publications about survodutide bring a focus that goes beyond a stale weight loss focus.

Despite this being prominent in the news, the first medication mentioned by GPs and IMs when asked Which drugs for managing of patients living with obesity are you aware of, even if you have not prescribed them? was, in 54% of responses, the much older and less effective orlistat and its brand names Xenical and Alli (figure 1)